Avidity Biosciences Sets February 12 Record Date for Spin-Off Ahead of Novartis Acquisition
RNA has more than doubled off its 52-week low of $21.51.
Summary
Avidity Biosciences announced the expected record date of February 12, 2026, for the pro rata distribution of Atrium Therapeutics, Inc. (SpinCo) shares to its stockholders, a key step in its proposed acquisition by Novartis AG.
Key Events · M&A and Partnerships · RNA
-
Spin-Off Record Date Set
Avidity Biosciences has designated February 12, 2026, as the record date for the pro rata distribution of Atrium Therapeutics, Inc. (SpinCo) shares.
-
Spin-Off Distribution Ratio
Stockholders will receive one share of SpinCo common stock for every ten shares of Avidity common stock held on the record date.
-
Part of Novartis Acquisition
This spin-off is a component of the previously announced proposed acquisition of Avidity Biosciences by Novartis AG.
-
Transaction Progress
The announcement of the record date signifies a material step forward in the execution of the merger and spin-off, following the definitive proxy statement filed on January 30, 2026.
Analysis · RNA · Life Sciences
This filing provides a key operational update regarding the previously announced acquisition by Novartis AG and the concurrent spin-off of Atrium Therapeutics, Inc. (SpinCo). The designation of a record date for the spin-off is a concrete step towards the completion of these significant corporate transactions, indicating progress in the deal's execution. Investors should note the 1-for-10 share distribution ratio for SpinCo common stock. The overall transaction, including the spin-off, remains subject to shareholder approval and other closing conditions.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RNA was trading at $72.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11B. The 52-week trading range was $21.51 to $72.76. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.